| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | -0.031 | 0.3 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.049 | 0.3 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.18 | 0.3 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.046 | 0.3 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.032 | 0.3 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | -0.05 | 0.3 |